- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06875102
Усталость при синдроме Шегрена: 3 терапевтические стратегии (FESSONA)
Усталость при синдроме Шегрена: рандомизированное контролируемое исследование комбинированных нефармакологических терапевтических стратегий
Unexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and feasible, but only to some extent. Hence, other therapeutic approaches, such as Acupuncture (ACU) or transcutaneous vagal nerve stimulation (tVNS), have been evaluated during the past years, with varying degrees of success in alleviating fatigue.
FESSONA has been designed as a randomized controlled monocentric trial, aiming at comparing the effects of 3 different programs on fatigue in SjS: APA alone, APA+ACU and APA+tVNS. Relevant controls will be included as well (sham ACU and simulated tVNS).
Multiple fatigue and SjS-related features will be measured before (at inclusion) and after (week 12) the intervention, as well as at week 24 and 48, to evaluate the short- and long-term impact of each program. Tolerance and feasibility will also be evaluated.
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Martin KILLIAN, MD
- Номер телефона: +33 (33)477 82 91 79
- Электронная почта: martin.killian@chu-st-etienne.fr
Учебное резервное копирование контактов
- Имя: Florence RANCON, Chef de projet
- Номер телефона: +33 (33)477829458
- Электронная почта: florence.rancon@chu-st-etienne.fr
Места учебы
-
-
-
Saint-Etienne, Франция, 42055
- Рекрутинг
- Chu de Saint-Etienne
-
Младший исследователь:
- David HUPIN, MD
-
Младший исследователь:
- Hubert MAROTTE, MD PhD
-
Младший исследователь:
- Baptiste GRAMONT, MD
-
Контакт:
- Martin KILLIAN, MD
- Номер телефона: +33 (33) 4 77 82 91 79
- Электронная почта: martin.killian@chu-st-etienne.fr
-
Контакт:
- Florence RANCON, Chef de projet
- Номер телефона: +33 (33) 4 77 82 94 58
- Электронная почта: florence.rancon@chu-st-etienne.fr
-
Младший исследователь:
- Lucile GRANGE, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Patient affiliated or entitled to a social security scheme.
- Age > 18 years.
- Patient informed and having signed the information form and consent to participate in the study.
- Patient with Sjögren's syndrome according to ACR/EULAR 2016 or AECG 2002 criteria, usually followed up every year or more frequently
- Fatigue present for ≥ 6 months, without obvious explanation and/or specific treatment to conduct (e.g., disease's flare, chronic infection), with a current FACIT-F score < 34
Exclusion Criteria:
- Pre-existing atrial fibrillation or severe cardiac conduction disorders,
- Recent stroke or myocardial infarction (<6 months),
- Left ventricular ejection fraction <40% or severe heart failure (New York Heart Association functional class III or IV)
- Recurrent episodes of vasovagal syncope, or history of vagotomy
- People with dermatological problems in the area where the stimulation electrodes are to be placed
- Current episode of venous or arterial thrombosis
- Pregnancy or breastfeeding
- Patient under protective measures (legal protection, curatorship, guardianship)
- Inability or refusal to understand and/or sign informed consent to participate in the study, or to perform follow-up examinations required under the study
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Apa + sham acu + tvns
|
Transcutaneous Vagus Nerve Stimulation (tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. In the groups receiving simulated tVNS, stimulation will be delivered to the ear lobe, which is devoid of vagal innervation. Stimulation will be delivered at a frequency of 20 Hz and a pulse width of 200 ms, while the stimulation amplitude will be individually titrated to 1 mA below the level that will lead to a mild unpleasant feeling, according to the parameters defined by Stavrakis et al (2017, 2020). The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention. |
|
Экспериментальный: APA + ACU + Смоделируемые TVNS
|
The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks acupoints will be Baihui (GV20); Zhongwan (CV12), Guanyuan (CV4), bilateral Zusanli (ST36) bilateral Taichong (LV3). The needles will remain for 30 min. Subjects will receive acupuncture twice a week during the 12-week intervention. Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in "simulated" mode. |
|
Фальшивый компаратор: APA + смоделирован TVNS + Sham ACU
|
The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention. Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in "simulated" mode. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in fatigue score assessed
Временное ограничение: Between inclusion (week 0) and visit V1 at 12 weeks (± 1 week from the end of the 12-week program)
|
Change in fatigue score assessed using the FACIT-F questionnaire (Functional Assessment of Chronic Illness Therapy - Fatigue; ranging from 0 to 52, 0 meaning extreme fatigue and 52 the total absence of fatigue) |
Between inclusion (week 0) and visit V1 at 12 weeks (± 1 week from the end of the 12-week program)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Пропорция (в %) из 24 сеансов APA, проведенных (не менее 80 % предложенных упражнений) в различных группах
Временное ограничение: Неделя 48
|
Неделя 48
|
|
|
FACIT-F score in the different groups
Временное ограничение: between inclusion (Week 0) and week 48
|
FACIT-F score at 48 weeks, in the different groups |
between inclusion (Week 0) and week 48
|
|
Root Mean Square of the Successive Differences in heart rate or RMSSD (in milliseconds)
Временное ограничение: at 12, 24 and 48 weeks,
|
Root Mean Square of the Successive Differences in heart rate or RMSSD (in milliseconds), measured from a nocturnal ECG recording by Holter ECG, in the different groups |
at 12, 24 and 48 weeks,
|
|
ClinESSDAI score
Временное ограничение: at 12, 24 and 48 weeks,
|
ClinESSDAI score (clinical part of the EULAR Sjögren's Syndrome Disease Activity Index; assessed on 11 "domains" corresponding to the main clinical manifestations of the disease; ranging from 0 to 135, a score of 0 meaning the existence of a disease and a score of 135 a disease whose activity would be maximal) in the different groups |
at 12, 24 and 48 weeks,
|
|
ESSPRI questionnaire (EULAR Sjögren's Syndrome Patient Reported Index)
Временное ограничение: at 12, 24 and 48 weeks
|
ESSPRI questionnaire (EULAR Sjögren's Syndrome Patient Reported Index); calculated as the mean of 3 self-measurement scales assessing fatigue, dryness and pain, each ranging from 0 to 10; 0 meaning the total absence of the symptom considered and 10 a symptom whose intensity would be at the maximum imaginable) in the different groups |
at 12, 24 and 48 weeks
|
|
HADS questionnaire (Hospital Anxiety and Depression Scale)
Временное ограничение: at 12, 24 and 48 weeks
|
HADS questionnaire (Hospital Anxiety and Depression Scale) composed of an anxiety score and a depression score both ranging from 0 to 21, 0 meaning the absence of symptoms of this type, and 21 the presence of an anxiety and/or major depressive state) in the different groups |
at 12, 24 and 48 weeks
|
|
Self-measurement questionnaire SF-36 (Short Form Health Survey 36)
Временное ограничение: between inclusion (Week 0) and week 48
|
Self-measurement questionnaire SF-36 (Short Form Health Survey 36); comprising 36 questions assessing 8 dimensions, namely physical functioning, role limitation due to physical problems, role limitation resulting from emotional problems, vitality (energy/fatigue), emotional well-being, social functioning, bodily pain, and perception of general and mental health; each dimension is represented by a score ranging from 0 to 100, with a low score signifying poor health perception in the dimension considered, and a high score signifying the opposite) |
between inclusion (Week 0) and week 48
|
|
EQ-5D-5L self-measurement questionnaire assessing 5 dimensions of health
Временное ограничение: at 12, 24, and 48 weeks,
|
EQ-5D-5L self-measurement questionnaire assessing 5 dimensions of health (mobility, autonomy, daily activities, pain/discomfort and anxiety/depression) with 1 question per domain, with the possibility of choosing 5 degrees of severity each time (1 corresponding to no difficulty for the domain and 5 corresponding to the maximum degree of difficulty in the domain), the total of the 5 notes of the 5 domains giving a score ranging from 5 to 25, and this questionnaire is associated with a visual analogue scale (VAS) allowing the patient to rate his state of health of the day from 0 (the worst state of health imaginable) to 100 (the best state of health imaginable), in the different groups |
at 12, 24, and 48 weeks,
|
|
Schirmer test
Временное ограничение: at 12, 24 and 48 weeks
|
the area of the graduated blotter that became wet after 5 min of placement on the lower eyelid of each eye, expressed in millimeters and as the average of the two eyes) at 12, 24 and 48 weeks, in the different groups |
at 12, 24 and 48 weeks
|
|
VO2max
Временное ограничение: at 12, 24 and 48 weeks
|
VO2max (in ml/min/kg; after metabolic test) in the different groups |
at 12, 24 and 48 weeks
|
|
Handgrip test
Временное ограничение: at 12, 24 and 48 weeks
|
Handgrip test (in kg; via a grip test on the dominant upper limb) in the different groups |
at 12, 24 and 48 weeks
|
|
Number of daily steps
Временное ограничение: at 12, 24 and 48 weeks
|
Number of daily steps measured via a connected watch on average over the week preceding the assessments at 12, 24 and 48 weeks, in the different groups |
at 12, 24 and 48 weeks
|
Соавторы и исследователи
Следователи
- Главный следователь: Martin KILLIAN, MD
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Заболевания опорно-двигательного аппарата
- Заболевания полости рта
- Стоматогнатические заболевания
- Артрит
- Заболевания суставов
- Ревматические заболевания
- Заболевания соединительной ткани
- Аутоиммунные заболевания
- Заболевания иммунной системы
- Глазные болезни
- Артрит, Ревматоидный
- Ксеростомия
- Заболевания слюнных желез
- Синдром сухого глаза
- Заболевания слезного аппарата
- Патологические состояния, признаки и симптомы
- Заболевания кожи и соединительной ткани
- Признаки и симптомы
- Усталость
- Синдром Шегрена
- Терапия
- Дополнительная терапия
- Гидролазы
- Ферменты
- Ферменты и коэнзименты
- Пептидные гидролазы
- Металлопротеазы
- Экзопептидазы
- Металлоэзопептидазы
- Аминопептидазы
- Акупунктурная терапия
- Глутамил аминопептидаза
Другие идентификационные номера исследования
- 24CH125
- ANSM (Другой идентификатор: 2024-A02116-41)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .